A Cross-sectional Study: Bone Markers in Different Body Mass Index Groups of Newly Diagnosed Breast Cancer Females in Karachi, Pakistan
Background: Pakistan is a big victim of breast cancer and vitamin D deficiency. Interestingly, bones are the common site of breast cancer metastasis and vitamin D deficiency makes this condition more worst. The present study designed to estimate bone markers and minerals in different BMI groups of newly diagnosed breast cancer patients. Materials & Methods: diagnosed breast cancer females were approached and their characteristics including age, marital status, menstrual & family history, receptor status, tumor grade & type and presence of metastasis were noted from their medical reports. Whereas bone markers and minerals viz., alkaline phosphatase (ALP), bone specific ALP (BALP), vitamin D, carboxyl terminal collagen crosslinks (CTX), human epidermal growth factor 2 receptor (Her2) protein, albumin, calcium (Ca), phosphorus (P) and magnesium (Mg) were estimated plus body mass index (BMI) measured. Results: Most of the recruited females found aged less than 50 yrs, wedded, belonged to plump to obese BMI groups, had invasive ductal carcinoma, expressed triple positive receptor status and tumor grade II. Very few had metastasis and family history of breast cancer. Patients in all BMI groups showed insufficient level of vitamin D but normal levels of ALP, Ca, Mg, P, albumin, Her2 protein and CTX. Whereas Ca and BALP found slightly low in underfed BMI group patients. Conclusion: The results concluded and recommended that vitamin D levels must be monitored in breast cancer patients before and after treatment otherwise it will decrease more and may affect other bone markers.
2. Sarwar MR, Saqib A. Cancer prevalence, incidence and mortality rate in Pakistan in 2012. Congent Medicine 2017; 4: 1288773.
3. Hodwell A, Anderson AS, Clarke RB, Duffy SW, Evans DG, Garcia-Closas M, Gescher AJ, Key TJ, Saxton JM, Harvie MN. Risk determination and prevention of breast cancer. Breast Can Res 2014; 16: 446.
4. Angaher LT. An overview of breast cancer epidemiology, risk factors, pathophysiology and cancer risk reduction. MedCrave Online J Biol Med 2017; 1: 00019.
5. Janbabai G, Shekarriz R, Hassanzadeh H, Aarabi M, Borhani SS. A survey on the relationship between serum 25-hydroxy vitamin D level and tumor characteristics in patients with breast cancer. Int J Hemat-Oncol Stem Cell Res 2016; 10: 30-36.
6. Atoum M, Alzoughool F. Vitamin D and breast cancer: Latest evidence and future steps. Breast Cancer: Basic and clinical research 2017; 11: 1–8
7. Fakkert IE, van der Veer E, Abma EM, Lefrandt JD, Wolffen buttel BHR, Oosterwijk JC, Slart RHJA, Westrik IG, de Bock GH, Mourits MJE. Elevated bone turnover markers after risk-reducing salpingo-oophorectomy in women at increased risk for breast and ovarian cancer. PLoS ONE 2017; 12: e0169673.
8. Colzani E, Clements M, Johansson ALV, Liljegren A, He W, Brand J, Adolfsson J, Fornander T, Hall P, Czene K. Risk of hospitalization and death due to bone fractures after breast cancer: A registry-based cohort study. Bri J Can 2016; 115: 1400–1407.
9. Shao T, Klein P, Grossbard ML. Vitamin D and breast cancer. Oncologist 2012; 17: 36–45.
10. Imtiaz S, Siddiqui N. Vitamin-D status at breast cancer diagnosis: Correlation with social and environmental factors and dietary intake. J Ayub Med Coll Abottabad 2014; 26: 186-190.
11. Tsang MN, Pai PC, Chuang CC, Tseng WCCCK, Chang KP, Yen TC, Lin JD, Chang JTC. Overweight and obesity predict better overall survival rates in cancer patients with distant metastases. Can Medicines 2016; 5: 665–675.
12. Shaukat N, Jaleel F, Moosa FA, Qureshi NA. Association between Vitamin D deficiency and breast cancer. Pak J Med Sci 2017; 33: 645-649.
13. Daly JA, Ertinghausen G. Direct method for determining inorganic phosphate in serum with the centrifichem. Clin Chem 1972; 18: 263-265.
14. Mann CK, Yoe JH. Spectrophotometric determination of magnesium with 1-azo-2-hydroxy-3-(2,4-dimethylcarboxanilido)-naphthalene-1’-(2- hydroxybenzene). Anal Chimica Acta 1957; 16:155-160.
15. Doumas BT, Watson WA, Biggs HG. Albumin standards and measurement of serum albumin with bromcresol green. Clinica Chimica Acta 1971; 31: 87–96.
16. Tietz NW, Burtis CA, Duncan P, Ervin K, Petitclerc CJ, Rinker AD, Shuey D, Zygowicz ER (1983). A reference method for measurement of alkaline phosphatase activity in human serum. Clin Chem 1983; 29: 751-61.
17. Freeman J, Wilson K, Spears R, Shalhoub V, Sibley P. Performance evaluation of four 25-hydroxyvitamin D assays to measure 25-hydroxyvitamin D2. Clin Biochem 2015; 48: 1097-104.
18. Payne RC, Allard JW, Anderson-Mauser L, Humphreys JD, Tenney DY, Morris DL. Automated assay for HER-2/neu in serum. Clin Chem 2000; 46: 175-82.
19. Swolin-Eide D, Hansson S, Larsson L, Magnusson P. The novel bone alkaline phosphatase b1x isoform in children with kidney disease. Ped Nephrol 2006; 21: 1723-1729.
20. Bonde M, Qvist P, Fledelius C, Riis BJ, Christiansen C (1994). Immunoassay for quantifying type I collagen degradation products in urine evaluated. Clin Chem 1994; 40: 2022-2025.
21. Mansha M, Saleem M, Wasim M, Tariq M. Prevalence of known risk factors in women diagnosed with breast cancer at Inmol hospital, Lahore, Punjab. Asian Pac J Can Prev 2016; 17: 563-568
22. Bano R, Ismail M, Nadeem A, Khan MH, Rashid H. Potential risk factors for breast cancer in Pakistani women. Asian Pac J Can Prev 2016; 17: 4307-4312.
23. Khodarahmi M, Azadbakht L. The association between different kinds of fat intake and breast cancer risk in women. Int J Prev Med 2014; 5: 6–15.
24. Howell A, Anderson AS, Clarke AB, Duffy SW, Evans DG, Garcia-Closas M, Gescher AJ, Key TJ, Saxton JM, Harvie MN. Risk determination and prevention of breast cancer. Breast Cancer Res 2014; 16: 446-464.
25. Berger NA. Obesity and cancer pathogenesis. Ann N Y Acad Sci 2014; 1311: 57–76.
26. Suzuki R, Saji S, Toi M. Impact of body mass index on breast cancer in accordance with the life-stage of women. Front Oncol 2012; 2: 123.
27. Leone JP, Leone BA. Breast cancer brain metastases: The last frontier. Exp Hemat Oncol 2015; 4: 33
28. Tan F, Xiao H, Gummadi S, Koniaris LG, Feldman JD, Ali AA, Adunlin G, Huang Y. Impact of body mass index on prognosis for breast cancer patients. J Women Health Gyn 2017; 4: 1-11.
29. Kakarala M, Rozek L, Cote M, Liyanage S, Brenner DE. Breast cancer histology and receptor status characterization in Asian Indian and Pakistani women in the U.S- A SEER analysis. BMC Cancer 2010; 10: 191.
30. Hashemi SHB, Karimi S, Mahboobi H. Lifestyle changes for prevention of breast cancer. Electron Physician 2014; 6: 894-905.
31. Pathak R, Jha A, Neupane PR, Chalise S, Basnyat AS. Histopathological evaluation of carcinoma of breast. J Pathol Nepal 2016; 6: 922 -927.
32. Kabel AM. Tumor markers of breast cancer: New prospective 2017. J Oncol Sci 2017; 3: 5e11
33. Jin X, Mu P. Targeting breast cancer metastasis. Breast Cancer (Auckl) 2015; 9 (Suppl 1): 23–34.
34. Gutierrez C, Schiff R. HER 2: Biology, detection, and clinical implications. Arch Pathol Lab Med 2011; 135: 55–62.
35. Hashmi AA, Edhi MM, Naqvi H, Faridi N, Khurshid A, Khan M. Clinicopathologic features of triple negative breast cancers: An experience from Pakistan. Diagn Pathol 2014; 9: 43-51.
36. Murphy CG, Modi S. HER2 breast cancer therapies: A review. Biologics 2009; 3: 289–301
37. Pulido C, Vendrell I, Ferreira AR, Casimiro S, Mansinho A, Alho I, Costa L. Bone metastasis risk factors in breast cancer. ecancer 2017; 11:715
38. Lipton A, Chapman J-AW, Demers L, Shepherd LE, Han L, Wilson CF, Pritchard KI, Leitzel KE, Ali SM, Pollak M. Elevated bone turnover predicts for bone metastasis in postmenopausal breast cancer: Results of NCICCTGMA.14. J Clin Oncol 2011; 29: 3605-3610.
39. Brown J, Rathbone E, Hinsley S, Gregory W, Gossiel F, Marshall H, Burkinshaw R, Shulver H, Thandar H, Bertelli G, Maccon K, Bowman A, Hanby A, Bell R, Cameron D, Coleman R. Associations between serum bone biomarkers in early breast cancer and development of bone metastasis: Results from the AZURE (BIG01/04) trial. JNCI J Natl Cancer Inst 2018; 110: djx280.
40. Imtiaz S, Siddiqui N, Raza SA, Loya A, Muhammad A. Vitamin D deficiency in newly diagnosed breast cancer patients. Ind J Endocrinol Metabolism 2012; 16: 409-413.
41. Younus A, Faiz M, Yasmeen A. Serum Vitamin D in women with pre and post-menopausal newly diagnosed breast cancer in Pakistan. J Food Nutri Res 2016; 4: 828-833.
42. Shamsi U, Khan S, Usman S, Soomro S, Azam I. A multicenter matched case control study of breast cancer risk factors among women in Karachi, Pakistan. Asian Pac J Can Prev 2013; 14: 183-8.
43. Singh IAK, Pandey A, Tewari M, Kumar R, Sharma A, Singh KA, Pandey HP, Shukla HS. Advanced stage of breast cancer hoist alkaline phosphatase activity: risk factor for females in India. 3 Biotech 2013; 3: 517–520.
44. Lim SM, Kim YN, Park KH, Kang B, Chon HJ, Kim C, Kim JH, Rha SY. Bone alkaline phosphatase as a surrogate marker of bone metastasis in gastric cancer patients. BMC Cancer 2016; 16: 385-391
45. Ramaswamy G, Rao VR, Krishnamoorthy L, Ramesh G, Gomathy R, Renukadevi D. Serum levels of bone alkaline phosphatase in breast and prostate cancers with bone metastasis. Ind J Clin Biochem 2000; 15: 110-113.
46. Voorzanger-Rousselot N, Juillet F, Mareau E, Zimmermann J, Kalebic T, Garnero P. Association of 12 serum biochemical markers of angiogenesis, tumour invasion and bone turnover with bone metastases from breast cancer: A crossectional and longitudinal evaluation. Bri J Cancer 2006; 95: 506 – 514.
47. Chen YY, Xu GB, Yang F. Effect of Neoadjuvant chemotherapy on the serum levels of bone turnover markers in women with early-stage breast cancer. PLOS ONE 2015; 14 pages.
48. Beto JA. The role of calcium in human aging. Clin Nutr Res 2015; 4: 1-8.
49. Lips P. Interaction between vitamin D and calcium. Scand J Clin Lab Invest (Suppl) 2012; 243: 60-64.
50. Kim W, Wysolmerski JJ. Calcium-sensing receptor in breast physiology and cancer. Front Physiol 2016; 7: Article 440.
51. Takeda E, Taketani Y, Sawada N, Sato T, Yamamoto H. The regulation and function of phosphate in the human body. Biofactors 2004; 21: 345-55.
52. Fukumoto S. Phosphate metabolism and vitamin D. Bonekey Rep. 2014; 3: 497-501.
53. Blaszczyk U, Duda-Chodak A. Magnesium: its role in nutrition and carcinogenesis. Rocz Panstw Zakl Hig 2013; 64: 165–171
54. Abdelgawad IA, El-Mously RH, Saber MM, Mansour OA, Shouman SA. Significance of serum levels of vitamin D and some related minerals in breast cancer patients. Int J Clin Exp Pathol 2015; 8: 4074–4082
55. Tao M-H, Dai Q, Millen AE, Nie J, Edge SB, Trevisan M, Shields PG, Freudenheim JL. Associations of intakes of magnesium and calcium and survival among women with breast cancer: results from Western New York exposures and breast cancer (WEB) study. Am J Cancer Res 2016; 6: 105–113.
56. Fujii T, Yajima R, Takada T, Sutoh T, Morita H, Yamaguchi S, Tsutsumi S, Kuwano H. Serum albumin and prealbumin do not predict recurrence in patients with breast Cancer. Anticancer Res 2014; 34: 3775-3780.
57. Kaur RP, Rubal, Dhiman M, Vashitstha R, Munshi A. Serum albumin levels in breast cancer: Correlation with overall survival. J Food Nutr Disord 2017; 6:5